Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Genentech Inc
Genentech Inc_20100107
Genentech Inc_20100114
Genentech Inc_20100128
Genentech Inc_20131212
Genentech Inc_20100121

Genentech Inc patents


Recent patent applications related to Genentech Inc. Genentech Inc is listed as an Agent/Assignee. Note: Genentech Inc may have other listings under different names/spellings. We're not affiliated with Genentech Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Genentech Inc-related inventors


 new patent  Anti-ly6e antibodies and immunoconjugates and methods of use

The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.... Genentech Inc

 new patent  Anti-cd79b antibodies and immunoconjugates

The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.... Genentech Inc

 new patent  Anti-wall teichoic antibodies and conjugates

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.... Genentech Inc

Therapeutic compounds and uses thereof

and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.... Genentech Inc

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such... Genentech Inc

Anti-cll-1 antibodies and immunoconjugates

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

Serine/threonine kinase inhibitors

Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.... Genentech Inc

Cysteine engineered antibodies and conjugates

where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.... Genentech Inc

Blood brain barrier receptor antibodies and methods of use

The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.... Genentech Inc

Heteroaryl estrogen receptor modulators and uses thereof

stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents,... Genentech Inc

Anti-transferrin receptor antibodies and methods of use

The present invention relates to anti-transferrin receptor antibodies and methods of their use.... Genentech Inc

Novel compounds and compositions for the inhibition of nampt

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:... Genentech Inc

Tricyclic dlk inhibitors and uses thereof

wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said... Genentech Inc

Anti-vegf antibodies

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Genentech Inc

Expression and secretion system

The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic... Genentech Inc

Treatment of th17 mediated inflammatory diseases

The present invention provides methods and means to reduce inflammation associated with IRF-4, AP-1 and TH17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions.... Genentech Inc

Bioanalytical analysis of site-specific antibody drug conjugates

Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.... Genentech Inc

Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject... Genentech Inc

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating... Genentech Inc

Compositions and methods for the treatment of tumor hematopoietic origin

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Genentech Inc

Antibodies against bace1 and use thereof for neural disease immunotherapy

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.... Genentech Inc

Serine/threonine kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in... Genentech Inc

Silvestrol antibody-drug conjugates and methods of use

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.... Genentech Inc

Hedgehog antagonists having zinc binding moieties

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.... Genentech Inc

Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders

The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.... Genentech Inc

Methods for treating progressive multiple sclerosis

The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.... Genentech Inc

Animal model for nephropathy and agents for treating the same

A non-human transgenic animal expressing ApoL1 is provided as well as a method for generating the same. Also provided is a method for identifying an agent capable of reducing the progression of an ApoL1 mediated nephropathy. Furthermore, an isolated antibody is provided which binds to the human variants of ApoL1.... Genentech Inc

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and... Genentech Inc

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods... Genentech Inc

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods... Genentech Inc

Anti-htra1 antibodies and methods of use

The invention provides anti-HtrA1 antibodies and methods of using the same.... Genentech Inc

Methods of using fgf19 modulators

Provided herein are methods of using FGF19 modulators and/or bile acid metabolism biomarkers.... Genentech Inc

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II)... Genentech Inc

11/23/17 / #20170334883

Therapeutic compounds and uses thereof

wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Genentech Inc

11/23/17 / #20170334985

Anti-il-13/il-17 bispecific antibodies and uses thereof

The invention provides anti-IL-13/IL-17 bispecific antibodies, in particular, anti-IL13/IL17 AA, AF and FF antibodies and methods of using the same, including without limitation, methods of using the anti-IL-13/IL-17 bispecific antibodies for treating moderate to severe asthma and/or eosinophilic asthma.... Genentech Inc

11/16/17 / #20170326248

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

11/16/17 / #20170327574

Methods of treating liver conditions using notch2 antagonists

Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.... Genentech Inc

11/09/17 / #20170319688

Anti-rspo3 antibodies and methods of use

Provided herein are anti-RSPO3 antibodies and methods of using the same.... Genentech Inc

11/09/17 / #20170320871

Tetrahydroisoquinoline estrogen receptor modulators and uses thereof

and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituent and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating... Genentech Inc

11/09/17 / #20170320926

Il-22 polypeptides and il-22 fc fusion proteins and methods of use

The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.... Genentech Inc

11/09/17 / #20170320937

Anti-influenza b virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.... Genentech Inc

11/09/17 / #20170320940

Anti-alpha-synuclein antibodies and methods of use

The present invention relates to anti-alpha-synuclein (anti-α-synuclein) antibodies and methods of using the same.... Genentech Inc

11/09/17 / #20170321187

Biologically active c-terminal arginine-containing peptides

The present invention concerns the separation, identification and characterization of active peptide fragments from peptones.... Genentech Inc

11/02/17 / #20170312252

Pyrrolidine amide compounds as histone demethylase inhibitors

The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Genentech Inc

11/02/17 / #20170312292

Therapeutic compounds and uses thereof

and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of... Genentech Inc

11/02/17 / #20170313704

Process for making tricyclic lactam compounds

Processes are described for the preparation of tricyclic lactam compound of Formula (I), having the structure and intermediates useful for the preparation of (I).... Genentech Inc

11/02/17 / #20170313780

Prevention of disulfide bond reduction during recombinant production of polypeptides

The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.... Genentech Inc

11/02/17 / #20170315132

Multiplexed total antibody and antibody-conjugated drug quantification assay

Methods are disclosed to detect, characterize, measure, and quantify human and humanized antibodies, and their conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.... Genentech Inc

10/26/17 / #20170304438

Methods of using anti-cd79b immunoconjugates

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.... Genentech Inc

10/26/17 / #20170306040

Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate.... Genentech Inc

10/26/17 / #20170306418

Therapeutic, diagnostic, and prognostic methods for cancer

The invention provides methods and compositions to detect expression of one or more biornarkers, including FGFR3, TP53, and/or EGFR, for treating, diagnosing, and providing a prognosis for cancer, e.g., bladder cancer. The invention also provides kits and articles of manufacture for use in the methods.... Genentech Inc

10/26/17 / #20170306419

Diagnostic markers

The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.... Genentech Inc

10/19/17 / #20170296550

Aryl sultam derivatives as rorc modulators

wherein m, n, p, q, Ar, A, W, X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.... Genentech Inc

10/12/17 / #20170290883

Vascular disruption agents and uses thereof

Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.... Genentech Inc

10/12/17 / #20170290913

Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.... Genentech Inc

10/12/17 / #20170290920

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

10/12/17 / #20170291940

Il-17a/f heterologous polypeptides and therapeutic uses thereof

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present... Genentech Inc

10/05/17 / #20170281619

Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective BCL-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.... Genentech Inc

10/05/17 / #20170281792

Anti-mesothelin antibodies and immunoconjugates

The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.... Genentech Inc

10/05/17 / #20170283424

Pyrazolopyrimidine jak inhibitor compounds and methods

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and... Genentech Inc

10/05/17 / #20170283505

Production of proteins in glutamine-free cell culture media

The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.... Genentech Inc

09/28/17 / #20170274073

Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists

The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.... Genentech Inc

09/28/17 / #20170274092

Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines

The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.... Genentech Inc

Patent Packs
09/28/17 / #20170275273

Estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon... Genentech Inc

09/28/17 / #20170275289

Therapeutic compounds and uses thereof

wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Genentech Inc

09/28/17 / #20170275359

Anti-ephrinb2 antibodies and methods using same

The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies.... Genentech Inc

09/28/17 / #20170276683

Elisa for vegf

The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in... Genentech Inc

09/14/17 / #20170260252

Production of heteromultimeric proteins using mammalian cells

Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.... Genentech Inc

09/14/17 / #20170260253

Cysteine engineered antibodies and conjugates

Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and... Genentech Inc

09/14/17 / #20170260292

Low affinity blood brain barrier receptor antibodies and uses thereof

The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.... Genentech Inc

09/14/17 / #20170260594

Methods and compositions for prognosis and treatment of cancers

The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may... Genentech Inc

09/07/17 / #20170252457

Process for the preparation of an antibody-rifamycin conjugate

and intermediates for conjugation with an antibody.... Genentech Inc

09/07/17 / #20170253661

Galactoengineered immunoglobulin 1 antibodies

The present invention relates to galactoengineered recombinant antibodies of IgG1 isotype, methods for the production of said antibodies and uses thereof.... Genentech Inc

09/07/17 / #20170253933

Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

The invention provides methods of using expression levels of one or more stroma signature genes as selection criteria for determining a patient with cancer that is chemotherapy-resistant who may benefit from a particular anti-cancer therapy, such as stroma-targeted therapy, anti-angiogenic therapy, and/or immunotherapy. The present invention also provides methods of... Genentech Inc

08/31/17 / #20170247337

Process for making hydroxylated cyclopentylpyrimidine compounds

and salts thereof, wherein R1 is defined herein, and compounds and intermediates of said formula.... Genentech Inc

08/31/17 / #20170247338

Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed... Genentech Inc

08/31/17 / #20170247381

Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase

The invention relates generally to pharmaceutical tablet compositions comprising fumaric acid and the compound (S)-2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one free base that is an inhibitor of Bruton's tyrosine kinase. The invention further relates to amorphous solid dispersions comprising at least one polymer and the Bruton's kinase inhibitor free base compound. The invention further relates... Genentech Inc

08/24/17 / #20170239219

Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer

Described herein are methods of treating locally advanced or metastatic estrogen receptor positive breast cancer.... Genentech Inc

Patent Packs
08/24/17 / #20170239246
08/24/17 / #20170239355

Use of tryptophan derivatives for protein formulations

The invention provides methods and formulations comprising a protein comprising solvent accessible amino acid residues susceptible to oxidation wherein N-acetyl tryptophan (NAT) is used to prevent oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. Methods to measure degradation of... Genentech Inc

08/24/17 / #20170239366

Anti-b7-h4 antibodies and immunoconjugates

The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

08/24/17 / #20170240620

Anti-polyubiquitin antibodies and methods of use

The invention provides anti-polyubiquitin antibodies and methods of using the same.... Genentech Inc

08/24/17 / #20170240645

Anti-pmel17 antibodies and immunoconjugates

The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

08/17/17 / #20170232113

Quaternary amine compounds and antibody-drug conjugates thereof

This invention relates to quaternary amine linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.... Genentech Inc

08/17/17 / #20170233407

Tricyclic p13k inhibitor compounds and methods of use

Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.... Genentech Inc

08/17/17 / #20170233471

Anti-lgr5 antibodies and uses thereof

The invention provides anti-LgR5 antibodies and methods of using the same.... Genentech Inc

08/17/17 / #20170233482

Combination therapy

The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a... Genentech Inc

08/17/17 / #20170233486

Polynucleotides encoding anti-notch1 nrr antibody polypeptides

The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.... Genentech Inc

08/17/17 / #20170233809

Methods for diagnosing and treating inflammatory bowel disease

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive... Genentech Inc

08/17/17 / #20170234883

Antibodies and immunoconjugates and uses therefor

Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.... Genentech Inc

08/10/17 / #20170224820

Compositions and methods useful for stabilizing protein-containing formulations

The invention relates to use of non-surfactant compounds including, for example, polyoxyethylene (POE) sorbitans and polyethylene glycols (PEGs), for stabilizing protein-containing formulations and for the prevention of aggregation of proteins in such formulations.... Genentech Inc

08/10/17 / #20170226132

Triazolopyridine compounds, compositions and methods of use thereof

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.... Genentech Inc

08/10/17 / #20170226198

Predicting response to a vegf antagonist

The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as... Genentech Inc

08/10/17 / #20170226224

Protein purification

A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one or more contaminants.... Genentech Inc

07/27/17 / #20170209444

Methods of treating cancer and preventing cancer drug resistance

Provided herein are methods of using antagonists of G9a, for example, for treating cancer and/or preventing drug resistance in an individual. For example, a method of treating cancer in an individual comprising administering to the individual an antagonist of G9a alone or in combination with a cancer therapy agent is... Genentech Inc

07/27/17 / #20170209444

Methods of treating cancer and preventing cancer drug resistance

Provided herein are methods of using antagonists of G9a, for example, for treating cancer and/or preventing drug resistance in an individual. For example, a method of treating cancer in an individual comprising administering to the individual an antagonist of G9a alone or in combination with a cancer therapy agent is... Genentech Inc

07/27/17 / #20170209593

Methods of conjugating an agent to a thiol moiety in a protein that contains at least one sulfide bond

The invention provides improved methods of conjugating an agent to a thiol moiety in a protein that contains at least one disulfide bond and at least one trisulfide bond. Exemplary embodiments include the production of antibody drug conjugates substantially free of impurities created in the presence of reactive sulfide moieties... Genentech Inc

07/27/17 / #20170210724

Alkynyl alcohols and methods of use

wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.... Genentech Inc

07/27/17 / #20170210733

Benzoxazepin oxazolidinone compounds and methods of use

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases... Genentech Inc

07/27/17 / #20170210807

Humanized anti-beta7 antagonists and uses therefor

The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.... Genentech Inc

07/27/17 / #20170210815

Compositions and methods for diagnosis and treatment of hepatic cancers

The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.... Genentech Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Genentech Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Genentech Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###